A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Mechanism of Action
Adagrasib is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C).
mutation (G12C).
Purpose
- How much of the study drug can be given with an acceptable level of side effects when given alone or in combination with Pembrolizumab, Cetuximab or Afatinib
- The effects of the study drug (good and bad) when given alone or in combination with Pembrolizumab, Cetuximab or Afatinib
- How much of the study drug is absorbed into the blood and how fast it is removed when given alone or in combination with Pembrolizumab, Cetuximab or Afatinib
- If research tests can be used in the future to predict who will benefit from the study drug
Location
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.